Phase Ib Study of Single Agent LDE225, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis

Trial Profile

Phase Ib Study of Single Agent LDE225, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 27 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 04 Nov 2015 Patients with Child-Pugh A/B7 cirrhosis were included in the study (previously patients with Child-Pugh A cirrhosis were included), according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top